

**2 June 2016**

**EKF Diagnostics Holdings plc  
("EKF" or the "Company")**

**Results of Placing**

EKF Diagnostics Holdings plc (AIM: EKF) announces the successful completion of the Placing announced this morning. A total of 42,205,707 Placing Shares have been placed at a price of 11.25 pence per Placing Share. The Placing will raise gross proceeds of approximately £4.75 million.

The Placing, conducted by Panmure Gordon as Nominated Adviser and Corporate Broker, is conditional, *inter alia*, on Admission. The Placing Shares will, when issued, be credited as fully paid and will rank *pari passu* in all respects with the existing Ordinary Shares.

Application will be made to the London Stock Exchange for admission to trading of 42,205,707 Placing Shares on AIM ("**Admission**"). It is expected that Admission will take place at 8.00 a.m. on 7 June 2016 (at which time the Placing will become unconditional) and that dealings in the Placing Shares on AIM will commence at the same time.

**Director dealings**

The Company has been notified that North Atlantic Smaller Companies Investment Trust PLC ("**NAIT**") and Oryx International Growth Fund Limited ("**Oryx**") participated in the Placing as detailed below. Harwood Capital LLP ("**Harwood**") is investment manager and investment adviser to NAIT and Oryx respectively. Christopher Mills, the Company's Non-Executive Chairman, is a partner and Chief Investment Officer of Harwood. Christopher Mills is also a director of Oryx and NAIT. He holds 2.16 per cent. of the shares in Oryx in his own name as well as a further 46.44 per cent. of the shares in Oryx via his 25.06 per cent. shareholding in NAIT.

Entity	Number of Placing Shares acquired pursuant to the terms of the Placing	Resulting holding post Admission	% of enlarged issued voting share capital
--------	---	--	--

Oryx	4,650,000	40,000,000	8.62%
NAIT	16,297,656	64,947,656	13.99%
<b>Total</b>	<b>20,947,656</b>	<b>104,947,656</b>	<b>22.61%</b>

The Company has also been notified today that certain other Directors of EKF have agreed to acquire Placing Shares pursuant to the terms of the Placing. The beneficial interests of the participating Directors will, on Admission, be as follows:

<i>Director</i>	<i>Number of Placing Shares acquired pursuant to the terms of the Placing</i>	<i>Resulting holding post Admission</i>	<i>% of enlarged issued voting share capital</i>
Julian Baines	133,333	1,855,288	0.40%
Adam Reynolds	88,889	3,318,613	0.71%

Defined terms used in this announcement have the same meaning as set out in the Placing announcement issued by the Company on 2 June 2016 unless otherwise stated.

## **Disclosure and Transparency Rules**

EKF's enlarged issued share capital immediately following the issue of the Placing Shares will be 464,262,781 ordinary shares, with one vote per ordinary share held. The aforementioned figure of 464,262,781 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in interest in, the share capital of the Company under the Disclosure and Transparency Rules.

### **EKF Diagnostics Holdings plc**

Julian Baines, CEO  
Richard Evans, FD & COO

**Tel: 029 2071 0570**

### **Panmure Gordon (UK) Limited**

Robert Naylor (Corporate Finance)  
Paul Fincham (Corporate Finance)  
Rupert Dearden (Sales)

**Tel: 020 7886 2500**

### **Walbrook PR Limited**

Paul McManus  
Lianne Cawthorne

**Tel: 020 7933 8780** or [ekf@walbrookpr.com](mailto:ekf@walbrookpr.com)  
Mob: 07980 541 893  
Mob: 07584 391 303

END

MSCUGUPCQUPQGCP admin Results of Placing 24493848 A Thu, 06/02/2016 - 15:44 Company  
Announcement - General EKF